amerson

Amerson Pharmaceuticals and Medical Products Services: China Entry Strategy, Actions Plans Formulation and Implementation
Not only does the lack of transparency in the regulation of the pharmaceutical industry make China a tough market, but the complexities of the country?s wide economic and demographic disparities preclude the adoption of a comprehensive, generalised view of the market as a whole.

Leveraging on our unique China specific local know-how and years of wide spanned experience on investment capital budgeting, project evaluation, and recommendation for our global and local clients in pharmaceuticals and medical products industry, Amerson has a broad investment consulting services offering in the market. Amerson helps your organizations achieve higher ROI through helping your decision making on:

  > Where to enter in China
  > Timing of Entry
  > Scale of Entry
  > Strategic Commitments
  > Modes of Entry
  > Strategic Alliances
  > Comprehensive project evaluation and accurate recommendation based on the following investment criteria:

   - Addition to EPS
   - Net Present Value (NPV)
   - Payback period
   - Discounted payback period
   - Average Accounting Return (AAR)
   - Internal Rate of Return (IRR)
   - Crossover Rate
   - Profitability Index (PI)

Action Plan and Execution Services